Kidney Ischemia and Reperfusion Injury – Field of Glory or Warterloo for Erythropoietin?
DOI:
https://doi.org/10.17140/NPOJ-1-e004Keywords:
Ischemia; Reperfusion; Hypoxia; Kidney; Animal model; ErythropoietinAbstract
When asking clinicians about their knowledge about Erythropoietin (EPO) most of
them would say that it increases Red Blood Cell (RBC) count and can therefore be used to
treat anemia, is produced in the kidneys and can be misused as doping agent in sports. The
way to reach this today’s common knowledge was long and hard. In the year 1667 by giving a
lambs blood to an anemic patient and the lucky outcome that the patient felt better afterwards,
it became clear that blood could heal.1
Over two centuries later in a rabbit experimental set-up
where plasma was transduced between an anemic and a healthy animal it could be seen that
the red blood cell count increased in the anemic one. This gave birth to the thesis that a humeral factor is responsible and was named hemopoietin.2
Seventy years later this mysterious
substance was found by Goldwasser in patients´ urine3
and was later on cloned by a colleague
of him4 what marked the beginning of EPOs therapeutic career in treating anemia that lasts on
until today.
References
Denis, JB. Concerning a new way of curing. Philosophical Transactions. 1667; 489-504.
Carnot P, Deflandre, C. On the hemopoietic activity of serum during the regeneration of blood. [French] C. R. Acad. Sci. 1906; 143: 348-387.
Goldwasser E. Erythropoietin: a somewhat personal history. Perspect Biol Med. 1996; 40(1): 18-32. doi: 10.1353/pbm.1996.0005
Lin F-K, Suggs S, Lin C-H, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci. 1985; 82: 7580- 7584.
Maiese K, Li F, Chung Z. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci. 2004; 25: 577-583. doi: 10.1016/j.tips.2004.09.006
Nakano M, Satoh K, Fukumoto Y, et al. Important role of erythropoietin receptor to promote VEGF expression and angiogenesis in peripheral ischemia in mice. Circ Res. 2007; 100: 662-669. doi: 10.1161/01.RES.0000260179.43672.fe
Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005; 293: 90-95. doi: 10.1001/jama.293.1.90
Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999; 55: 808-820.
Spandou E, Tsouchnikas I, Karkavelas G, et al. Erythropoietin attenuates renal injury in experimental acute renal failure isch-aemic/reperfusion model. Nephrol Dial Transplant. 2006; 21: 330-336. doi: 10.1093/ndt/gfi177
Sharples EJ, Patel N, Brown P, et al. Erythropoietin protects the kidney against injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol. 2004; 15: 2115-2124. doi: 10.1097/01.ASN.0000135059.67385.5D
Ates E, Yalcin AU, Yilmaz S, Koken T, Tokyol C. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg. 2005; 75: 1100-1105. doi: 10.1111/j.1445-2197.2005.03612.x
Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int. 2006; 69: 1806-1813.
Maio R, Sepodes B, Patel NS, Thiemermann C, Mota-Filipe H, Costa P. Erythropoietin preserves the integrity and quality of organs for transplantation after cardiac death. Shock. 2011; 35: 126-133. doi: 10.1097/SHK.0b013e3181e83236
Forman CJ, Johnson DW, Nicol DL. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int. 2007; 99: 162-165. doi: 10.1111/j.1464-410X.2006.06505.x
Sølling C, Christensen AT, Krag S, et al. Erythropoietin administration is associated with short term improvement in glomerular filtration rate after ischemia-reperfusion injury. Acta Anaesthesiol Scand. 2011; 55: 185-195. doi: 10.1111/j.1399-6576.2010.02369.x
Ishii Y, Sawada T, Murakami T, et al. Renoprotective effect of erythropoietin against ischaemia reperfusion injury in a non-human primate model. Nephrol Dial Transplant. 2011; 26: 1157-1162. doi: 10.1093/ndt/gfq601
Aydin Z, Mallat MJ, Schaapherder AF, et al. Randomized trial of short course high-dose erythropoietin in donation after cardiac death kidney transplant recipients. Am J Transplant. 2012; 12: 1793-1800. . doi: 10.1111/j.1600-6143.2012.04019.x
Hafer C, Becker T, Kielstein JT, et al. High-dose erythropoietin has no effect on short- or long-term graft function following deceased donor kidney transplantation. Kidney Int. 2012; 81: 314-320. doi: 10.1038/ki.2011.349
Martinez F, Kamar N, Pallet N, et al. High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: results of the Neo-PDGF Study. Am J Transplant. 2010; 10: 1695-1700. doi: 10.1111/j.1600-6143.2010.03142.x
Sureshkumar KK, Hussain SM, Ko TY, Thai NL, Marcus RJ. Effect of high-dose erythropoietin on graft function after kidney transplantation: a randomized, double-blind clinical trial. Clin J Am Soc Nephrol. 2012; 7: 1498-1506.
Song YR, Lee T, You SJ, et al. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery by pass grafting: a pilot study. Am J Nephrol. 2009; 30: 253-260. doi: 10.1159/000223229
deSeigneux S, Ponte B, Weiss L, et al. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol. 2012; 13: 132. doi: 10.1186/1471-2369-13-132
Matejkova S, Scheuerle A, Wagner F, et al. Carbamylated erythropoietin-FC fusion protein and recombinant human erythropoi-etin during porcine kidney ischemia/reperfusion injury. Intensive Care Med. 2013; 39(3): 497-510. doi: 10.1007/s00134-012-2766-y
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.